USD 169.5
(-0.56%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 6.56 Billion USD | -2.58% |
2022 | 6.73 Billion USD | -0.07% |
2021 | 6.74 Billion USD | -0.22% |
2020 | 6.75 Billion USD | 10.59% |
2019 | 6.11 Billion USD | -5.15% |
2018 | 6.44 Billion USD | 30.08% |
2017 | 4.95 Billion USD | 10.85% |
2016 | 4.46 Billion USD | 0.11% |
2015 | 4.46 Billion USD | 22.51% |
2014 | 3.64 Billion USD | 0.03% |
2013 | 3.64 Billion USD | 615.52% |
2012 | 509 Million USD | -11.48% |
2011 | 575 Million USD | -14.56% |
2010 | 673 Million USD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q3 | 6.75 Billion USD | 0.17% |
2024 Q2 | 6.56 Billion USD | 0.02% |
2024 Q1 | 6.56 Billion USD | -0.03% |
2023 Q4 | 6.56 Billion USD | -2.65% |
2023 FY | 6.56 Billion USD | -2.58% |
2023 Q2 | 6.74 Billion USD | 0.06% |
2023 Q3 | 6.74 Billion USD | 0.0% |
2023 Q1 | 6.73 Billion USD | 0.01% |
2022 Q4 | 6.73 Billion USD | 24.87% |
2022 FY | 6.73 Billion USD | -0.07% |
2022 Q2 | 5.38 Billion USD | -0.07% |
2022 Q1 | 5.38 Billion USD | -20.12% |
2022 Q3 | 5.39 Billion USD | 0.26% |
2021 Q2 | 6.73 Billion USD | -0.1% |
2021 Q3 | 6.75 Billion USD | 0.19% |
2021 FY | 6.74 Billion USD | -0.22% |
2021 Q1 | 6.74 Billion USD | -0.18% |
2021 Q4 | 6.74 Billion USD | -0.13% |
2020 Q4 | 6.75 Billion USD | -0.06% |
2020 FY | 6.75 Billion USD | 10.59% |
2020 Q1 | 6.12 Billion USD | 0.18% |
2020 Q2 | 7.34 Billion USD | 20.04% |
2020 Q3 | 6.76 Billion USD | -7.99% |
2019 Q4 | 6.11 Billion USD | -7.63% |
2019 Q1 | 6.57 Billion USD | 2.1% |
2019 Q2 | 6.61 Billion USD | 0.56% |
2019 Q3 | 6.61 Billion USD | 0.02% |
2019 FY | 6.11 Billion USD | -5.15% |
2018 Q4 | 6.44 Billion USD | 0.03% |
2018 FY | 6.44 Billion USD | 30.08% |
2018 Q3 | 6.44 Billion USD | 29.99% |
2018 Q2 | 4.95 Billion USD | 0.02% |
2018 Q1 | 4.95 Billion USD | 0.02% |
2017 Q3 | 4.95 Billion USD | 33.15% |
2017 FY | 4.95 Billion USD | 10.85% |
2017 Q2 | 3.71 Billion USD | 0.03% |
2017 Q1 | 3.71 Billion USD | -16.79% |
2017 Q4 | 4.95 Billion USD | 0.02% |
2016 FY | 4.46 Billion USD | 0.11% |
2016 Q1 | 4.46 Billion USD | 0.02% |
2016 Q3 | 4.46 Billion USD | 0.04% |
2016 Q2 | 4.46 Billion USD | 0.02% |
2016 Q4 | 4.46 Billion USD | 0.02% |
2015 FY | 4.46 Billion USD | 22.51% |
2015 Q2 | 3.24 Billion USD | 0.0% |
2015 Q4 | 4.46 Billion USD | 38.34% |
2015 Q3 | 3.22 Billion USD | -0.52% |
2015 Q1 | 3.24 Billion USD | -10.98% |
2014 Q1 | 3.64 Billion USD | 0.0% |
2014 Q2 | 3.64 Billion USD | 0.0% |
2014 Q3 | 3.64 Billion USD | 0.0% |
2014 Q4 | 3.64 Billion USD | 0.03% |
2014 FY | 3.64 Billion USD | 0.03% |
2013 FY | 3.64 Billion USD | 615.52% |
2013 Q1 | 3.64 Billion USD | 615.13% |
2013 Q2 | 3.64 Billion USD | 0.0% |
2013 Q3 | 3.64 Billion USD | 0.05% |
2013 Q4 | 3.64 Billion USD | 0.0% |
2012 Q4 | 509 Million USD | -12.24% |
2012 Q2 | 573 Million USD | -1.04% |
2012 Q3 | 580 Million USD | 1.22% |
2012 FY | 509 Million USD | -11.48% |
2012 Q1 | 579 Million USD | 0.7% |
2011 FY | 575 Million USD | -14.56% |
2011 Q4 | 575 Million USD | 0.0% |
2010 FY | 673 Million USD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Editas Medicine, Inc. | 24.37 Million USD | -26832.546% |
Dynavax Technologies Corporation | 252.41 Million USD | -2500.448% |
Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -19673.467% |
Perrigo Company plc | 3.63 Billion USD | -80.687% |
Illumina, Inc. | 1.48 Billion USD | -340.833% |
Thermo Fisher Scientific Inc. | 31.3 Billion USD | 79.034% |
Iovance Biotherapeutics, Inc. | 1 Million USD | -656300.0% |
Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 18.399% |
IQVIA Holdings Inc. | 12.95 Billion USD | 49.332% |
Heron Therapeutics, Inc. | 173.75 Million USD | -3677.776% |
Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | -142.85% |
Unity Biotechnology, Inc. | 23.53 Million USD | -27785.637% |
Waters Corporation | 2.3 Billion USD | -184.709% |
Biogen Inc. | 7.18 Billion USD | 8.684% |
Sangamo Therapeutics, Inc. | 33.51 Million USD | -19485.26% |
Evolus, Inc. | 120.35 Million USD | -5353.684% |
Adicet Bio, Inc. | 17.7 Million USD | -36978.461% |
Cara Therapeutics, Inc. | 37.07 Million USD | -17602.743% |
bluebird bio, Inc. | 224.41 Million USD | -2824.886% |
Esperion Therapeutics, Inc. | 501.54 Million USD | -1208.753% |
FibroGen, Inc. | 89.69 Million USD | -7217.971% |
Agilent Technologies, Inc. | 2.73 Billion USD | -140.0% |
Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -202578.23% |
Homology Medicines, Inc. | 43.17 Million USD | -15102.89% |
Geron Corporation | 35.05 Million USD | -18626.998% |
Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | -180.151% |
Amicus Therapeutics, Inc. | 387.85 Million USD | -1592.372% |
Myriad Genetics, Inc. | 130.9 Million USD | -4914.515% |
Viking Therapeutics, Inc. | 936 Thousand USD | -701182.051% |
Intellia Therapeutics, Inc. | 96.74 Million USD | -6684.707% |
Abeona Therapeutics Inc. | 4.4 Million USD | -149014.039% |
Mettler-Toledo International Inc. | 1.97 Billion USD | -232.262% |
BioMarin Pharmaceutical Inc. | 593.09 Million USD | -1006.737% |
Vertex Pharmaceuticals Incorporated | 724.7 Million USD | -805.754% |
Kala Pharmaceuticals, Inc. | 34.19 Million USD | -19098.596% |
Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | -368.731% |
Atara Biotherapeutics, Inc. | 45.69 Million USD | -14265.439% |
Verastem, Inc. | 40.08 Million USD | -16274.794% |
Nektar Therapeutics | 112.62 Million USD | -5728.191% |
Axsome Therapeutics, Inc. | 178.07 Million USD | -3586.191% |
Aclaris Therapeutics, Inc. | 3.07 Million USD | -213432.856% |
Sarepta Therapeutics, Inc. | 1.13 Billion USD | -479.595% |
OPKO Health, Inc. | 222.03 Million USD | -2856.304% |
Exelixis, Inc. | 189.94 Million USD | -3355.755% |
Neurocrine Biosciences, Inc. | 258.3 Million USD | -2441.231% |
Corcept Therapeutics Incorporated | - USD | -Infinity% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
uniQure N.V. | 130.06 Million USD | -4946.707% |
Imunon, Inc. | 1.13 Million USD | -576046.786% |
Blueprint Medicines Corporation | 610.96 Million USD | -974.371% |
Insmed Incorporated | 1.19 Billion USD | -450.047% |
Halozyme Therapeutics, Inc. | 1.49 Billion USD | -337.819% |
Agios Pharmaceuticals, Inc. | 56.98 Million USD | -11418.214% |
TG Therapeutics, Inc. | 100.11 Million USD | -6456.264% |
Incyte Corporation | 29.16 Million USD | -22408.744% |
Emergent BioSolutions Inc. | 446.5 Million USD | -1370.101% |